U.S. Markets closed
  • S&P 500

    4,431.85
    +105.34 (+2.43%)
     
  • Dow 30

    34,725.47
    +564.69 (+1.65%)
     
  • Nasdaq

    13,770.57
    +417.79 (+3.13%)
     
  • Russell 2000

    1,968.51
    +37.22 (+1.93%)
     
  • Crude Oil

    87.29
    +0.68 (+0.79%)
     
  • Gold

    1,790.10
    -3.00 (-0.17%)
     
  • Silver

    22.49
    -0.19 (-0.82%)
     
  • EUR/USD

    1.1152
    +0.0005 (+0.0446%)
     
  • 10-Yr Bond

    1.7820
    -0.0250 (-1.38%)
     
  • Vix

    27.66
    -2.83 (-9.28%)
     
  • GBP/USD

    1.3401
    +0.0019 (+0.1447%)
     
  • USD/JPY

    115.1900
    -0.1120 (-0.0971%)
     
  • BTC-USD

    37,795.71
    +1,145.70 (+3.13%)
     
  • CMC Crypto 200

    863.83
    +21.37 (+2.54%)
     
  • FTSE 100

    7,466.07
    -88.24 (-1.17%)
     
  • Nikkei 225

    26,717.34
    +547.04 (+2.09%)
     

Immunogen: Q1 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • IMGN

Shares of Immunogen (NASDAQ:IMGN) gained 10% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were up 43.33% over the past year to ($0.17), which missed the estimate of ($0.15).

Revenue of $13,287,000 higher by 54.79% from the same period last year, which missed the estimate of $14,940,000.

Outlook

Immunogen hasn't issued any earnings guidance for the time being.

Immunogen hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: May 01, 2020

View more earnings on IMGN

Time: 12:00 PM ET

Webcast URL: https://edge.media-server.com/mmc/p/38zm7g3c

Recent Stock Performance

Company's 52-week high was at $7.07

Company's 52-week low was at $1.76

Price action over last quarter: down 30.78%

Company Overview

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.